Gd-Tex Pharmacyclics Inc.

Current Opinion in Investigational Drugs

Volumn 1, Issue 4, 2000, Pages 524-528

  Radford, I R ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM TEXAPHYRIN; LIVER ENZYME;

BRAIN METASTASIS; BRAIN TUMOR; CLINICAL TRIAL; CONTRAST ENHANCEMENT; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG TOLERANCE; GAMMA KNIFE RADIOSURGERY; HUMAN; IRRADIATION; KIDNEY TUBULE NECROSIS; LUNG TUMOR; NONHUMAN; PANCREAS TUMOR; RADIOSENSITIZATION; REVIEW; TREATMENT OUTCOME;

ANIMALS; CLINICAL TRIALS; DRUGS, INVESTIGATIONAL; HUMANS; NEOPLASMS; ORGANOMETALLIC COMPOUNDS; RADIATION-SENSITIZING AGENTS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0034537460     PISSN: 09678298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Pharmacyclis initiates phase Ib/II trial of GD-TEX for use in treatment of cancer patients receiving radiation therapy. Phase I clinical study confirms tumor selective localization
2. Pharmacyclics announces NCI decision network approval to collaborate on two anti-cancer compounds
3. Pharmacyclics announces interim results of Gd-Tex results presented at American Society of Clinical Oncology Meeting
4. Lutetium texaphyrin (PCI-0123): A near-infrared, water-soluble photosensitizer
5. NCI to sponsor 9 clinical studies with Pharmacyclics' Gd-Tex
6. Pharmacyclics reports first quarter results
7. Pharmacyclics announces interim Gd-Tex results at American Society of Clinical Oncology Meeting: Survival analyses indicate treatment with Gd-Tex leads to improved outcome
8. Pharmacyclics announces start of National Cancer Institute-sponsored Gd-Tex radiation sensitizer trials at UCLA
9. Pharmacyclics announces start of phase III GD-TEX trial for brain metastases
10. Pharmacyclics announces Gd-Tex results at American Society of Therapeutic Radiology and Oncology meeting. Reduction in deaths due to neurologic progression and favorable effect on survival reported in phase Ib/II for brain metastases
11. Pharmacyclics begins phase III of radiation sensitizing agent
12. Pharmacyclics reports third quarter results
13. Pharmacyclics reports promising results from lead-in phase of ongoing phase III clinical trial of Xcytrin for brain metastases
14. Pharmacyclics announces publication of preclinical data supporting Xcytrin's clinical activity and novel mechanism of action
15. Pharmacyclics announces start of phase I trial of Xcytrin in childhood gliomas
16. Annual Report 1999 - Pharmacyclics Inc
17. Multicenter study shows that new agent enhances effects of radiation in patients with brain metastases
18. Pharmacyclics reports on status of ongoing phase III clinical trial of Xcytrin for brain metastases: Neurocognitive lead-in data presented at ASCO
19. Neurocognitive function (NF) predicts outcome in patients with brain metastases (BM) treated with whole brain radiation (WBRT) and xcytrin
20. Pharmacyclics reports progress of ongoing phase III clinical trial of Xcytrin for brain metastases: Clinical investigators expect to complete enrollment by end of 2000
21. Texaphyrins: New drugs with diverse clinical applications in radiation and photodynamic therapy
22. Re-evaluating gadolinium(III) texaphyrin as a radiosensitizing agent
23. In vivo animal studies with gadolinium (III) texaphyrin as a radiation enhancer
24. Phases IB and II multidose trial of gadolinium texaphyrin, a radiation sensitizer detectable at MR imaging: Preliminary results in brain metastases
25. A phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging
26. Clinical trials referral resource. Clinical trials with gadolinium-texaphyrin and lutetium-texaphyrin
27. Gadolinium(III) texaphyrin: A tumor selective radiation sensitizer that is detectable by MRI
28. One-electron reduction and oxidation studies of the radiation sensitizer gadolinium(III) texaphyrin (PCI-0120) and other water soluble metallotexaphyrins
29. Pharmacyclics announces start of NCI-sponsored phase I clinical trials of Xcytrin in primary lung cancer and with stereotactic radiosurgery for advanced brain tumors
30. Pharmacyclics reports promising results from lead-in phase of ongoing phase III trial of Xcytrin for brain metastases: Company also reports preliminary results from ongoing phase I trial of Xcytrin for primary brain tumors
31. Gd-Tex: Comments on in vitro studies